A study published in JAMA Neurology indicates that individuals who survive Ebola often face enduring neurological impairments, including persistent memory loss. This discovery comes as the World Health Organisation (WHO) manages a current outbreak of the Bundibugyo virus, which has been declared an international health emergency.

The 148 survivors and the persistence of memory loss

Researchers from JAMA Neurology tracked 148 people who had previously contracted the Ebola virus over a period of nearly ten years. According to the report, these patients experienced a range of neurological issues, including altered mental status, headaches, and symptoms consistent with meningitis. While many of these symptoms improved after seven years, a significant number of survivors continued to struggle with cognitive deficits, most notably memory loss.

The study authors argue that these findings necessitate a fundamental shift in how the medical community treats the virus. They claim that Ebola virus disease (EVD) should be officially recognised as a neurotropic disease—one that specifically attacks the nervous system—which creates an urgent need for therapeutic interventions designed to protect the brain during and after infection.

Protected sites and the 'mini-stroke' effect in the brain

Professor Paul Hunter, a virus expert at the University of East Anglia, explains that the virus can hide in "protected sites" within the body, such as the brain, where the immune system is unable to eliminate it. As reported in the source, this lingering infection can lead to chronic neurological damage. professor Hunter notes that the evidence for post-viral syndrome in Ebola survivors is significantly stronger than the current evidence for "long COVID."

Beyond the viral presence, the physical trauma of the infection contributes to long-term brain damage. the virus often causes a series of small bleeds in the brain, which Professor Hunter compares to mini-strokes. Additionally, the psychological trauma of facing a near-death experience is believed to have a lasting impact on the brain's function.

The Bundibugyo variant and the Oxford vaccine race

The current health crisis is driven by the Bundibugyo virus, a rare variant first recorded in 2007 in western Uganda and again in 2012 in the Democratic Republic of the Congo (DRC). Unlike more common strains of Ebola, the Bundibugyo variant currently has no licensed vaccine to help contain its spread. This lack of pharmaceutical protection increases the risk of a large-scale epidemic.

Scientists at Oxford University are currently working to develop a specific vaccine for the Bundibugyo strain. However , the report notes that it will take two to three months before this jab can undergo human testing, meaning patients in Africa are unlikely to receive the drug within the next six months. furthermore, there is no guarantee that this experimental vaccine will prove effective once tested.

598 confirmed cases and the CDC's warning of record scale

The World Health Organisation (WHO) declared the current situation an international health emergency on May 17 after detecting cases in Uganda and the DRC. The government of Congo has stated that confirmed Ebola cases have risen to 598, resulting in 115 deaths. This surge has prompted the US Centers for Disease Control and Prevention (CDC) to warn that the outbreak could reach a scale similar to the worst in history, such as the 2014-2016 West Africa outbreak that killed 11,000 people.

The threat is not limited to the immediate region; the African Union's primary public health agency considers ten nearby countries to be at risk. In the UK,the NHS has already instructed staff to prepare for a potential outbreak. While the exact origin of the Bundibugyo variant remains unknown, some researchers suspect it was transmitted to humans via fruit bats.